Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy

Yun Chi Lu, Chih Hung Chuang, Kuo Hsiang Chuang, I. Ju Chen, Bo Cheng Huang, Wen Han Lee, Hsin Ell Wang, Jia Je Li, Yi An Cheng, Kai Wen Cheng, Jaw Yuan Wang, Yuan Chin Hsieh, Wen Wei Lin, Tian Lu Cheng

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

During rheumatoid arthritis (RA) treatment, long-term injection of antitumor necrosis factor α antibodies (anti-TNFα Abs) may induce on-target toxicities, including severe infections (tuberculosis [TB] or septic arthritis) and malignancy. Here, we used an immunoglobulin G1 (IgG1) hinge as an Ab lock to cover the TNFα-binding site of Infliximab by linking it with matrix metalloproteinase (MMP) -2/9 substrate to generate pro-Infliximab that can be specifically activated in the RA region to enhance the selectivity and safety of treatment. The Ab lock significantly inhibits the TNFα binding and reduces the anti-idiotypic (anti-Id) Ab binding to pro-Infliximab by 395-fold, 108-fold compared with Infliximab, respectively, and MMP-2/9 can completely restore the TNFα neutralizing ability of pro-Infliximab to block TNFα downstream signaling. Pro-Infliximab was only selectively activated in the disease site (mouse paws) and presented similar pharmacokinetics (PKs) and bio-distribution to Infliximab. Furthermore, pro-Infliximab not only provided equivalent therapeutic efficacy to Infliximab but also maintained mouse immunity against Listeria infection in the RA mouse model, leading to a significantly higher survival rate (71%) than that of the Infliximab treatment group (0%). The high-selectivity pro-Infliximab maintains host immunity and keeps the original therapeutic efficiency, providing a novel strategy for RA therapy.

Original languageEnglish
Pages (from-to)e3000286
JournalPLoS Biology
Volume17
Issue number6
DOIs
Publication statusPublished - Jun 1 2019

Fingerprint

rheumatoid arthritis
Rheumatoid Arthritis
Chemical activation
Safety
therapeutics
gelatinase A
immunity
listeriosis
mice
arthritis
Therapeutics
tuberculosis
neutralization
immunoglobulins
pharmacokinetics
binding sites
necrosis
Matrix Metalloproteinase 2
Matrix Metalloproteinase 9
survival rate

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy. / Lu, Yun Chi; Chuang, Chih Hung; Chuang, Kuo Hsiang; Chen, I. Ju; Huang, Bo Cheng; Lee, Wen Han; Wang, Hsin Ell; Li, Jia Je; Cheng, Yi An; Cheng, Kai Wen; Wang, Jaw Yuan; Hsieh, Yuan Chin; Lin, Wen Wei; Cheng, Tian Lu.

In: PLoS Biology, Vol. 17, No. 6, 01.06.2019, p. e3000286.

Research output: Contribution to journalArticle

Lu, YC, Chuang, CH, Chuang, KH, Chen, IJ, Huang, BC, Lee, WH, Wang, HE, Li, JJ, Cheng, YA, Cheng, KW, Wang, JY, Hsieh, YC, Lin, WW & Cheng, TL 2019, 'Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy', PLoS Biology, vol. 17, no. 6, pp. e3000286. https://doi.org/10.1371/journal.pbio.3000286
Lu, Yun Chi ; Chuang, Chih Hung ; Chuang, Kuo Hsiang ; Chen, I. Ju ; Huang, Bo Cheng ; Lee, Wen Han ; Wang, Hsin Ell ; Li, Jia Je ; Cheng, Yi An ; Cheng, Kai Wen ; Wang, Jaw Yuan ; Hsieh, Yuan Chin ; Lin, Wen Wei ; Cheng, Tian Lu. / Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy. In: PLoS Biology. 2019 ; Vol. 17, No. 6. pp. e3000286.
@article{2fa386c4f90942cd9948c478105d894b,
title = "Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy",
abstract = "During rheumatoid arthritis (RA) treatment, long-term injection of antitumor necrosis factor α antibodies (anti-TNFα Abs) may induce on-target toxicities, including severe infections (tuberculosis [TB] or septic arthritis) and malignancy. Here, we used an immunoglobulin G1 (IgG1) hinge as an Ab lock to cover the TNFα-binding site of Infliximab by linking it with matrix metalloproteinase (MMP) -2/9 substrate to generate pro-Infliximab that can be specifically activated in the RA region to enhance the selectivity and safety of treatment. The Ab lock significantly inhibits the TNFα binding and reduces the anti-idiotypic (anti-Id) Ab binding to pro-Infliximab by 395-fold, 108-fold compared with Infliximab, respectively, and MMP-2/9 can completely restore the TNFα neutralizing ability of pro-Infliximab to block TNFα downstream signaling. Pro-Infliximab was only selectively activated in the disease site (mouse paws) and presented similar pharmacokinetics (PKs) and bio-distribution to Infliximab. Furthermore, pro-Infliximab not only provided equivalent therapeutic efficacy to Infliximab but also maintained mouse immunity against Listeria infection in the RA mouse model, leading to a significantly higher survival rate (71{\%}) than that of the Infliximab treatment group (0{\%}). The high-selectivity pro-Infliximab maintains host immunity and keeps the original therapeutic efficiency, providing a novel strategy for RA therapy.",
author = "Lu, {Yun Chi} and Chuang, {Chih Hung} and Chuang, {Kuo Hsiang} and Chen, {I. Ju} and Huang, {Bo Cheng} and Lee, {Wen Han} and Wang, {Hsin Ell} and Li, {Jia Je} and Cheng, {Yi An} and Cheng, {Kai Wen} and Wang, {Jaw Yuan} and Hsieh, {Yuan Chin} and Lin, {Wen Wei} and Cheng, {Tian Lu}",
year = "2019",
month = "6",
day = "1",
doi = "10.1371/journal.pbio.3000286",
language = "English",
volume = "17",
pages = "e3000286",
journal = "PLoS Biology",
issn = "1544-9173",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy

AU - Lu, Yun Chi

AU - Chuang, Chih Hung

AU - Chuang, Kuo Hsiang

AU - Chen, I. Ju

AU - Huang, Bo Cheng

AU - Lee, Wen Han

AU - Wang, Hsin Ell

AU - Li, Jia Je

AU - Cheng, Yi An

AU - Cheng, Kai Wen

AU - Wang, Jaw Yuan

AU - Hsieh, Yuan Chin

AU - Lin, Wen Wei

AU - Cheng, Tian Lu

PY - 2019/6/1

Y1 - 2019/6/1

N2 - During rheumatoid arthritis (RA) treatment, long-term injection of antitumor necrosis factor α antibodies (anti-TNFα Abs) may induce on-target toxicities, including severe infections (tuberculosis [TB] or septic arthritis) and malignancy. Here, we used an immunoglobulin G1 (IgG1) hinge as an Ab lock to cover the TNFα-binding site of Infliximab by linking it with matrix metalloproteinase (MMP) -2/9 substrate to generate pro-Infliximab that can be specifically activated in the RA region to enhance the selectivity and safety of treatment. The Ab lock significantly inhibits the TNFα binding and reduces the anti-idiotypic (anti-Id) Ab binding to pro-Infliximab by 395-fold, 108-fold compared with Infliximab, respectively, and MMP-2/9 can completely restore the TNFα neutralizing ability of pro-Infliximab to block TNFα downstream signaling. Pro-Infliximab was only selectively activated in the disease site (mouse paws) and presented similar pharmacokinetics (PKs) and bio-distribution to Infliximab. Furthermore, pro-Infliximab not only provided equivalent therapeutic efficacy to Infliximab but also maintained mouse immunity against Listeria infection in the RA mouse model, leading to a significantly higher survival rate (71%) than that of the Infliximab treatment group (0%). The high-selectivity pro-Infliximab maintains host immunity and keeps the original therapeutic efficiency, providing a novel strategy for RA therapy.

AB - During rheumatoid arthritis (RA) treatment, long-term injection of antitumor necrosis factor α antibodies (anti-TNFα Abs) may induce on-target toxicities, including severe infections (tuberculosis [TB] or septic arthritis) and malignancy. Here, we used an immunoglobulin G1 (IgG1) hinge as an Ab lock to cover the TNFα-binding site of Infliximab by linking it with matrix metalloproteinase (MMP) -2/9 substrate to generate pro-Infliximab that can be specifically activated in the RA region to enhance the selectivity and safety of treatment. The Ab lock significantly inhibits the TNFα binding and reduces the anti-idiotypic (anti-Id) Ab binding to pro-Infliximab by 395-fold, 108-fold compared with Infliximab, respectively, and MMP-2/9 can completely restore the TNFα neutralizing ability of pro-Infliximab to block TNFα downstream signaling. Pro-Infliximab was only selectively activated in the disease site (mouse paws) and presented similar pharmacokinetics (PKs) and bio-distribution to Infliximab. Furthermore, pro-Infliximab not only provided equivalent therapeutic efficacy to Infliximab but also maintained mouse immunity against Listeria infection in the RA mouse model, leading to a significantly higher survival rate (71%) than that of the Infliximab treatment group (0%). The high-selectivity pro-Infliximab maintains host immunity and keeps the original therapeutic efficiency, providing a novel strategy for RA therapy.

UR - http://www.scopus.com/inward/record.url?scp=85068167623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068167623&partnerID=8YFLogxK

U2 - 10.1371/journal.pbio.3000286

DO - 10.1371/journal.pbio.3000286

M3 - Article

C2 - 31194726

AN - SCOPUS:85068167623

VL - 17

SP - e3000286

JO - PLoS Biology

JF - PLoS Biology

SN - 1544-9173

IS - 6

ER -